Skip to main content

Table 3 Adverse events, classified according to NCI CTCAE v5.0 the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, based on the worst grade for each patient and each type of toxicity

From: Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer

No. of patients (%)

During NACT

During CCRT

During follow-up

Toxicity

Any Grade

Grade ≥ 3

Any Grade

Grade ≥ 3

Grade ≥ 3

Any hematological toxicity

41 (82.0)

20 (40.0)

48 (96.0)

26 (52.0)

1 (2.0)

Anemia

18 (36.0)

3 (6.0)

38 (76.0)

19 (38.0)

1 (2.0)

Neutropenia

35 (70.0)

18 (36.0)

42 (84.0)

12 (24.0)

0 (0)

Thrombocytopenia

3 (6.0)

0 (0)

25 (50.0)

8 (16.0)

0 (0)

Any non hematological toxicity

49 (98.0)

16 (32.0)

43 (86.0)

16 (32.0)

1 (2.0)

Nausea

43 (86.0)

4 (8.0)

31 (62.0)

7 (14.0)

0 (0)

Vomiting

30 (60.0)

6 (12.0)

19 (38.0)

1 (2.0)

0 (0)

Constipation

14 (28.0)

1 (2.0)

12 (24.0)

0 (0)

0 (0)

Diarrhea

14 (28.0)

3 (6.0)

19 (38.0)

4 (8.0)

1 (2.0)

Fatigue

36 (72.0)

7 (14.0)

37 (74.0)

10 (20.0)

0 (0)

Alopecia

45 (90.0)

-

36 (72.0)

-

-

Anal pain

0 (0)

0 (0)

18 (36.0)

3 (6.0)

1 (2.0)

Peripheral Neuropathy

3 (6.0)

0 (0)

15 (30.0)

0 (0)

0 (0)

Creatinine Elevation

1 (2.0)

0 (0)

10 (20.0)

0 (0)

0 (0)

Hepatic Enzyme Elevation

1 (2.0)

1 (2.0)

8 (16.0)

2 (4.0)

0 (0)

  1. Adverse event that occurred during treatment and within 14 days of treatment completion